新型免疫药销售强劲提振业绩，艾伯维上调全年每股收益指引

智通财经网2025-04-25

艾伯维公司周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。不过，该公司表示，此次业绩指引调整未考虑任何潜在贸易政策变化，包括美国可能对医药行业加征的关税。近期医药板块整体承压，过去一个月来，由于投资者担忧特朗普政府可能对医药行业加征关税并启动行业调查，艾伯维及其他大型药企股价均大幅下挫。本周早些时候，同行默沙东预估将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1163245994?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/5feec0644a8d1136c6b84a44ba3b744e","is_english":false,"pubTime":"2025-04-25 20:58","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"1163245994","market":"us","top_or_hot":-1,"title":"新型免疫药销售强劲提振业绩，艾伯维上调全年每股收益指引","media":"智通财经网","content":"<div>\n<p>艾伯维公司周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。不过，该公司表示，此次业绩指引调整未考虑任何潜在贸易政策变化，包括美国可能对医药行业加征的关税。近期医药板块整体承压，过去一个月来，由于投资者担忧特朗普政府可能对医药行业加征关税并启动行业调查，艾伯维及其他大型药企股价均大幅下挫。本周早些时候，同行默沙东预估将...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1285354.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新型免疫药销售强劲提振业绩，艾伯维上调全年每股收益指引</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新型免疫药销售强劲提振业绩，艾伯维上调全年每股收益指引\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 20:58 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/content/detail/1285354.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>艾伯维公司周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。不过，该公司表示，此次业绩指引调整未考虑任何潜在贸易政策变化，包括美国可能对医药行业加征的关税。近期医药板块整体承压，过去一个月来，由于投资者担忧特朗普政府可能对医药行业加征关税并启动行业调查，艾伯维及其他大型药企股价均大幅下挫。本周早些时候，同行默沙东预估将...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1285354.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://www.zhitongcaijing.com/content/detail/1285354.html","article_id":"1163245994","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/5feec0644a8d1136c6b84a44ba3b744e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163245994","pubTimestamp":1745585901,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"公司第一季度业绩超出华尔街预期。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ABBV":"艾伯维公司"},"translate_title":"AbbVie raises full-year earnings per share guidance as strong sales of new immune drugs boost results","themeId":"f73c010b47e79b0d54e67ca51446cdbd","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/d953402f313367522ef34d194f58361c","symbols_score_info":{"ABBV":1.1},"content_text":"艾伯维公司周五宣布上调2025年盈利预期，得益于其新型免疫药物Skyrizi和Rinvoq的强劲销售表现，公司第一季度业绩超出华尔街预期。不过，该公司表示，此次业绩指引调整未考虑任何潜在贸易政策变化，包括美国可能对医药行业加征的关税。近期医药板块整体承压，过去一个月来，由于投资者担忧特朗普政府可能对医药行业加征关税并启动行业调查，艾伯维及其他大型药企股价均大幅下挫。本周早些时候，同行默沙东预估将产生2亿美元关税相关成本。根据最新年报披露，艾伯维在全球拥有600余处生产基地，其中爱尔兰作为其明星产品肉毒杆菌Botox的重要生产基地占据重要地位。财务数据显示，艾伯维的旗舰关节炎药物Humira第一季度全球销售额同比腰斩至11.2亿美元，低于13.2亿美元的预期。这已是该款曾全球销售额第一的药物连续第三个季度未达预期，目前其正面临十余种低价生物类似药的激烈竞争。为应对Humira销售下滑，艾伯维正全力推广Skyrizi和Rinvoq两款新药，并预测这两种新药在2027年将产生超过310亿美元的收入。本季度Skyrizi销售额达34.3亿美元，超过了华尔街预期的31.5亿美元，而Rinvoq的销售额为17.2亿美元，高于15.9亿美元的预期。第一季度经调整后每股收益2.46美元，高于分析师平均预测的2.38美元。展望未来，该公司预计其全年调整后每股收益将在12.09美元至12.29美元之间，而此前的预期为11.99美元至12.19美元。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163245994","isCrawlerRequest":true}